Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C82363
http://purl.obolibrary.org/obo/NCIT_C82363
Preferred Name

Golvatinib
Definitions
An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.
prefLabel
Golvatinib
label
Golvatinib
PDQ_Closed_Trial_Search_ID
640626
code
C82363
Has_Target
prefixIRI
NCIT:C82363
in_subset
Display_Name
Golvatinib
Preferred_Name
Golvatinib
FDA_UNII_Code
516Z3YP58E
Contributing_Source
CTRP
FDA
Chemical_Formula
C33H37F2N7O4
Maps_To
Golvatinib
CAS_Registry
928037-13-2
NCI_Drug_Dictionary_ID
640626
Legacy Concept Name
c-Met_VEGFR_Kinase_Inhibitor_E7050
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
640626
Semantic_Type
Pharmacologic Substance
UMLS_CUI
C3642430
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display